DESCRIPTION / DEFINITIONS: Lunesta® (eszopiclone) is an Anxiolytic, Sedative & Hypnotic drug prescribed for the treatment of insomnia. According to its label, “The clinical trials performed in support of efficacy were up to 6 months in duration. The final formal assessments of sleep latency and maintenance were performed at 4 weeks in the 6-week study, at the end of both 2-week studies and at the end of the 6-month study.”
ABUSE: Lunesta can have withdrawal symptoms. Lunesta is a Schedule IV Controlled Subtance.
ADDICTION / DEPENDENCE: Half Life and Metabolism.
SIDE EFFECTS: Anxiety, headache, viral infection, dry mouth (see list below).
WITHDRAWAL SYMPTOMS: Neurosis, insomnia, anxiety (see list below).
TREATMENT: Medical detoxification.
Lunesta® (eszopiclone) is an Anxiolytic, Sedative & Hypnotic drug prescribed for the treatment of insomnia. According to its label, “Because sleep disturbances may be the presenting manifestation of a physical and/or psychiatric disorder, symptomatic treatment of insomnia should be initiated only after a careful evaluation of the patient. The failure of insomnia to remit after 7 to 10 days of treatment may indicate the presence of a primary psychiatric and/or medical illness that should be evaluated.”
The label also states, “The precise mechanism of action of eszopiclone as a hypnotic is unknown, but its effect is believed to result from its interaction with GABA-receptor complexes at binding domains located close to or allosterically coupled to benzodiazepine receptors.”
Lunesta can have withdrawal symptoms. Lunesta is a Schedule IV Controlled Subtance.
HALF LIFE AND METABOLISM
The biological half life of a substance is the time it takes for a drug to lose half of its pharmacologic activity. This is significant because it affects how soon withdrawal symptoms may appear.
The half life of Lunesta is approximately 6 hours.
Lunesta is mainly metabolized through the P450 pathway in the liver and the enzymes primarily handling the metabolism is CYP3A4 and CYP2E1 but it is not clear how much of the metabolism is done by other enzymes.
The CYP enzymes are the major enzymes involved in drug metabolism, and since many drugs may increase or decrease the activity of various CYP isozymes, this is a major source of adverse drug interactions, since changes in CYP enzyme activity may affect the metabolism and clearance of various drugs. For example, if one drug inhibits the CYP-mediated metabolism of another drug, the second drug may accumulate within the body to toxic levels, possibly causing an overdose.
The following information is taken from the Lunesta label:
Lunesta can be a very difficult drug to stop taking.
Withdrawal from Lunesta should only be done under the care of a health practitioner. The safest way is to withdraw at an inpatient medical detox facility with a protocol that includes hydration, vitamins and supplements for biological balancing. Call us to talk to a Novus Detox Advisor.